An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
← catalyst calendarNCT07234032 · readout in 1,617 d
Sponsored by Insmed Incorporated (industry) · INSM — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
344estimated
Sites
9
Countries
Japan, South Korea, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-20 | actual | When the study began enrolling |
| Primary completion | 2031-01-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-22 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pulmonary Hypertension
- Interstitial Lung Disease
Interventions
- Drug: Treprostinil Palmitil Inhalation Powder — also filed as INS1009
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)
measured Up to 108 weeks
Permalink · INSM's whole pipeline · Catalyst calendar · Every registered study · What changed